2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Elderly
PAPER

415 Impact of early geriatric assessment and interventions on clinical outcomes in older patients with newly diagnosed multiple myeloma: From frailty to intervention.

Elham Askari, MD, Ana Isabel Hormigo-Sánchez, MD, PhD2, Amalia Domingo González, MD3, Alberto Eterio Velasco, MD4, Marina Menéndez Cuevas, MD5, Cristina Gonzalez de Villaumbrosia, MD6, Andrea Sáenz de Tejada Granados, MD7, Raquel Mata Serna, MD8, Rocio Nieves Salgado Sanchez, MD9, Berta Gracia Corral, MD10, Juan Fernando Bastidas Tamayo, MD11, Begoña Gutiérrez San José, MD12, Ignacio Mahillo, PhD13, Pilar Llamas Sillero, MD, PhD14, Raul Cordoba, MD, PhD15, Javier De La Rubia, MD, PhD16
1 University Hospital Fundación Jiménez Díaz, Madrid, Spain
2 University Hospital Fundación Jiménez Díaz, Madrid, Spain
3 University Hospital Fundación Jiménez Díaz, Madrid, Spain
4 University Hospital Rey Juan Carlos, Madrid, Spain
5 University Hospital Rey Juan Carlos, Madrid, Spain
6 University Hospital Rey Juan Carlos, Madrid, Spain
7 University Hospital Rey Juan Carlos, Madrid, Spain
8 University Hospital Fundación Jiménez Díaz, Madrid, Spain
9 University Hospital Fundación Jiménez Díaz, Madrid, Spain
10 University Hospital Fundación Jiménez Díaz, Madrid, Spain
11 University Hospital Fundación Jiménez Díaz, Madrid, Spain
12 University Hospital Fundación Jiménez Díaz, Madrid, Spain
13 University Hospital Fundación Jiménez Díaz, Madrid, Spain
14 University Hospital Fundación Jiménez Díaz, Madrid, Spain
15 MD Anderson Cancer Center, Madrid, Spain
16 University Hospital La Fe. Catholic University of Valencia, Valencia, Spain

Introduction

Frailty is an established prognostic factor for survival in older patients with multiple myeloma (MM). Since 2015, the International Myeloma Working Group-frailty score (IMWG-FS) has been widely used to identify frail patients. However, whether early geriatric assessment (GA) and GA-guided management (GAM) improve outcomes in frail and pre-frail patients remains unclear, particularly in real-world cohorts of older adults treated with novel therapies.

Methods

We retrospectively analyzed 110 patients aged ≥70 years with newly diagnosed multiple myeloma (NDMM) treated at 2 institutions between 2016 and 2024.  All patients prospectively underwent GA at diagnosis, evaluating physical and cognitive function, comorbidities, polypharmacy, nutritional and emotional status, and social support. Based on a multidimensional GA following International Society of Geriatric Oncology, patients were classified as fit, pre-frail, frail, or palliative. Patients with identified deficits received GAM, including frailty-based treatment adjustments and geriatric interventions. The primary objective was to evaluate the impact of GAM on clinical outcomes across frailty groups. The secondary objective was to externally validate the IMWG-FS.

Results

The median age was 80.3 years (range, 69-94); 84% were aged >75 years and 45% were >80 years. The median time from diagnosis to GA was 21.5 days (IQR, 8–43.5). Despite the advanced age of the cohort, GA classified 25.5% of patients as fit, 42% pre-frail, 29% frail, and 3.5% as palliative. In contrast, the IMWG-FS classified 11%, 23%, and 66% as fit, intermediate-fit, and frail, respectively. Half of GA-defined fit and pre-frail patients were classified as frail by the IMWG-FS, while all GA-frail patients met IMWG-FS criteria for frailty (P<0.001). Frailty-based treatment adjustments were implemented in 63.3% of patients (61% of pre-frail and 84% of frail patients, P<0.001). Overall, 74.7% received ≥1 geriatric intervention, most commonly a structured physical activity program (56%), while 27% required nutritional supplementation. Daratumumab, bortezomib, and lenalidomide-based regimens were prescribed in 40%, 56%, and 65% of patients, respectively. Lenalidomide was the most frequently dose-adjusted agent among GA-frail patients.
After a median follow-up of 2.65 years (IQR, 1.84–4.02), GA-defined fit and pre-frail patients had comparable overall survival (OS; HR, 1.51; 95% CI, 0.63–3.65; P=0.355) and progression-free survival (PFS; HR, 1.28; 95% CI, 0.60–2.74; P=0.523). In contrast, GA-frail patients had significantly inferior OS (HR, 4.88; 95% CI, 2.10–11.4; P<0.001) and PFS (HR, 3.75; 95% CI, 1.81–7.76; P<0.001) compared with GA-fit. Three-year OS was 84.5%, 70.3%, and 37.4% in fit, pre-frail, and frail, respectively, and PFS was 63.8%, 57.2%, and 22.3%. Similarly, no significant differences in OS or PFS were observed between IMWG-fit and intermediate-fit patients according IMWG-FS (OS: P=0.062; PFS: HR, 6.06; 95% CI, 0.79–46.6; P=0.084), whereas IMWG-frail patients had significantly inferior OS (P=0.004) and PFS (HR, 9.76; 95% CI, 1.34–70.9; P=0.024) compared with IMWG-fit patients. Rates of grade ≥3 hematologic and non-hematologic adverse events were comparable across GA frailty groups (P=0.655 and P=0.152, respectively). However, treatment discontinuation was significantly more frequent among GA-frail (60%) than in pre-frail (27.9%) and fit patients (14.8%; P<0.001). GA demonstrated superior prognostic discrimination compared with the IMWG-FS, with higher C-indices for both OS (0.683 vs. 0.611) and PFS (0.656 vs. 0.590). Only 14% of patients experienced frailty deterioration after treatment initiation.

Conclusions

This is the first study to report outcomes following GA and GA-guided interventions in a real-world cohort of older patients with NDMM. GA demonstrated superior prognostic performance compared with the IMWG-FS. Importantly, GA-defined pre-frail patients had outcomes comparable to fit patients, suggesting potential reversibility of vulnerability through early detection of geriatric impairments and targeted intervention. Conversely, GA-frail patients, with greater multidimensional geriatric impairment beyond chronological age, remained at high risk of mortality despite GAM. These findings highlight the value of GA for frailty risk stratification and guiding individualized treatment adjustments, supporting its integration into frontline management for older patients with NDMM.

Elham Askari, MD: Sanofi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)